The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Melanoma Cell Expression of Fas(Apo-1/CD95) Ligand: Implications for Tumor Immune Escape
Abstract
Malignant melanoma accounts for most of the increasing mortality from skin cancer. Melanoma cells were found to express Fas (also called Apo-1 or CD95) ligand (FasL). In metastatic lesions, Fas-expressing T cell infiltrates were proximal to FasL + tumor cells. In vitro, apoptosis of Fas-sensitive target cells occurred upon incubation with melanoma tumor cells; and in vivo, injection of FasL + mouse melanoma cells in mice led to rapid tumor formation. In contrast, tumorigenesis was delayed in Fas-deficient lpr mutant mice in which immune effector cells cannot be killed by FasL. Thus, FasL may contribute to the immune privilege of tumors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation.
Gavrieli, Y., Sherman, Y., & Ben-Sasson, S. A. (1992) · The Journal of cell biology · doi:10.1083/jcb.119.3.493 · Cited by 9,444
Nagata, S., & Golstein, P. (1995) · Science · doi:10.1126/science.7533326 · Cited by 3,979
Suda, T., Takahashi, T., Golstein, P., & Nagata, S. (1993) · Cell · doi:10.1016/0092-8674(93)90326-l · Cited by 2,489
Rosenberg, S. A., Packard, B. S., Aebersold, P. M., Solomon, D., Topalian, S. L., Toy, S. T., Simon, P., Lotze, M. T., Yang, J. C., Seipp, C. A., et al. (1988) · New England Journal of Medicine · doi:10.1056/nejm198812223192527 · Cited by 2,389
Fas Ligand-Induced Apoptosis as a Mechanism of Immune Privilege
Griffith, T. S., Brunner, T., Fletcher, S. M., Green, D. R., & Ferguson, T. A. (1995) · Science · doi:10.1126/science.270.5239.1189 · Cited by 2,005
Selection of Successive Tumour Lines for Metastasis
FIDLER, I. J. (1973) · Nature New Biology · doi:10.1038/newbio242148a0 · Cited by 1,361
Tumor Antigens Recognized by T Lymphocytes
Boon, T., Cerottini, J.-C., Van den Eynde, B., van der Bruggen, P., & Van Pel, A. (1994) · Annual Review of Immunology · doi:10.1146/annurev.iy.12.040194.002005 · Cited by 1,221
Self-citationA role for CD95 ligand in preventing graft rejection
Bellgrau, D., Gold, D., Selawry, H., Moore, J., Franzusoff, A., & Duke, R. C. (1995) · Nature · doi:10.1038/377630a0 · Cited by 1,155
Cytolytic T-cell cytotoxicity is mediated through perforin and Fas lytic pathways
Lowin, B., Hahne, M., Mattmann, C., & Tschopp, J. (1994) · Nature · doi:10.1038/370650a0 · Cited by 1,051
Self-citationMetalloproteinase-mediated release of human Fas ligand.
Kayagaki, N., Kawasaki, A., Ebata, T., Ohmoto, H., Ikeda, S., Inoue, S., Yoshino, K., Okumura, K., & Yagita, H. (1995) · The Journal of experimental medicine · doi:10.1084/jem.182.6.1777 · Cited by 822
Singer, G. G., & Abbas, A. K. (1994) · Immunity · doi:10.1016/1074-7613(94)90067-1 · Cited by 691
Expression of the functional soluble form of human fas ligand in activated lymphocytes.
Tanaka, M., Suda, T., Takahashi, T., & Nagata, S. (1995) · The EMBO Journal · doi:10.1002/j.1460-2075.1995.tb07096.x · Cited by 638
Protection against a lethal dose of endotoxin by an inhibitor of tumour necrosis factor processing
Mohler, K. M., Sleath, P. R., Fitzner, J. N., Cerretti, D. P., Alderson, M., Kerwar, S. S., Torranee, D. S., Otten-Evans, C., Greenstreet, T., Weerawarna, K., et al. (1994) · Nature · doi:10.1038/370218a0 · Cited by 588
Muul, L. M., Spiess, P. J., Director, E. P., & Rosenberg, S. A. (1987) · The Journal of Immunology · doi:10.4049/jimmunol.138.3.989 · Cited by 486
Ferrone, S., & Marincola, F. M. (1995) · Immunology Today · doi:10.1016/0167-5699(95)80033-6 · Cited by 474
French, L. E., Hahne, M., Viard, I., Radlgruber, G., Zanone, R., Becker, K., Müller, C., & Tschopp, J. (1996) · The Journal of cell biology · doi:10.1083/jcb.133.2.335 · Cited by 448
Self-citationPrevention of Islet Allograft Rejection with Engineered Myoblasts Expressing FasL in Mice
Lau, H. T., Yu, M., Fontana, A., & Stoeckert, C. J. (1996) · Science · doi:10.1126/science.273.5271.109 · Cited by 445
Self-citationMature T cells of autoimmune lpr/lpr mice have a defect in antigen-stimulated suicide.
Russell, J. H., Rush, B., Weaver, C., & Wang, R. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.10.4409 · Cited by 398
Braun, M. Y., Lowin, B., French, L., Acha-Orbea, H., & Tschopp, J. (1996) · The Journal of experimental medicine · doi:10.1084/jem.183.2.657 · Cited by 297
Self-citationGenes Coding for Tumor Antigens Recognized by Cytolytic T Lymphocytes
Pel, A. V., Van Der Bruggen, P., Coulie, P. G., Brichard, V. G., Lethéa, B., Van Den Eynde, B., Uyttenhove, C., Renauld, J., & Boon, T. (1995) · Immunological Reviews · doi:10.1111/j.1600-065x.1995.tb00084.x · Cited by 218
Regulation of cell surface APO‐1/Fas (CD95) ligand expression by metalloproteases
Mariani, S. M., Matiba, B., Bäumler, C., & Krammer, P. H. (1995) · European Journal of Immunology · doi:10.1002/eji.1830250828 · Cited by 217
Local Fas/APO‐1 (CD95) ligand‐mediated tumor cell killing in vivo
Rensing‐Ehl, A., Frei, K., Flury, R., Matiba, B., Mariani, S. M., Weller, M., Aebischer, P., Krammer, P. H., & Fontana, A. (1995) · European Journal of Immunology · doi:10.1002/eji.1830250821 · Cited by 191
Self-citationHuber, D., Philipp, J., & Fontana, A. (1992) · The Journal of Immunology · doi:10.4049/jimmunol.148.1.277 · Cited by 81
Self-citationCharacterization of the non-functional Fas ligand of gld mice
Hahne, M., Peitsch, M. C., Irmler, M., Schröter, M., Lowln, B., Rousseau, M., Bron, C., Renno, T., French, L. E., & Tschopp, J. (1995) · International Immunology · doi:10.1093/intimm/7.9.1381 · Cited by 67
Self-citationComparison of Fas(Apo-1/CD95)- and perforin-mediated cytotoxicity in primary T lymphocytes
Lowin, B., Mattmann, C., Hahne, M., & Tschopp, J. (1996) · International Immunology · doi:10.1093/intimm/8.1.57 · Cited by 59
Self-citationHahn, S., Stalder, T., Wernli, M., Bürgin, D., Tschopp, J., Nagata, S., & Erb, P. (1995) · European Journal of Immunology · doi:10.1002/eji.1830250942 · Cited by 41
Self-citation
Cited by
Death Receptors: Signaling and Modulation
Ashkenazi, A., & Dixit, V. M. (1998) · Science · doi:10.1126/science.281.5381.1305 · Cited by 5,866
Nagata, S. (1997) · Cell · doi:10.1016/s0092-8674(00)81874-7 · Cited by 4,938
Inhibition of death receptor signals by cellular FLIP
Irmler, M., Thome, M., Hahne, M., Schneider, P., Hofmann, K., Steiner, V., Bodmer, J.-L., Schröter, M., Burns, K., Mattmann, C., et al. (1997) · Nature · doi:10.1038/40657 · Cited by 2,563
Self-citationTumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo.
Walczak, H., Miller, R. E., Ariail, K., Gliniak, B., Griffith, T. S., Kubin, M., Chin, W., Jones, J., Woodward, A., Le, T., et al. (1999) · Nature Medicine · doi:10.1038/5517 · Cited by 2,497
Immunosuppressive Strategies that are Mediated by Tumor Cells
Rabinovich, G. A., Gabrilovich, D., & Sotomayor, E. M. (2007) · Annual Review of Immunology · doi:10.1146/annurev.immunol.25.022106.141609 · Cited by 1,702
Metadata
- Authors
- Hahne, M., Rimoldi, D., Schröter, M., Romero, P., Schreier, M., French, L. E., Schneider, P., Bornand, T., Fontana, A., Lienard, D., Cerottini, J.-C., & Tschopp, J.
- Venue
- Science
- Published
- 1996-11-22
- Volume
- 274
- Issue
- 5291
- Pages
- 1363-1366
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2016198585
- Cited by
- 1,249
- References
- 26
- FWCI
- 44.90
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.